International prescribing practices in obsessive-compulsive disorder (OCD)

Imagem de Miniatura
Arquivos
art_BRAKOULIAS_International_prescribing_practices_in_obsessivecompulsive_disorder_OCD_2016.PDF (86.48 KB)
Citações na Scopus
22
Tipo de produção
article
Data de publicação
2016
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
WILEY-BLACKWELL
Autores
BRAKOULIAS, Vlasios
STARCEVIC, Vladan
BELLOCH, Amparo
DELL'OSSO, Liliana
FERRAO, Ygor A.
FONTENELLE, Leonardo F.
LOCHNER, Christine
MARAZZITI, Donatella
MARTIN, Andrew
MATSUNAGA, Hisato
Citação
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, v.31, n.4, p.319-324, 2016
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
ObjectivesTo assess rates of psychotropic medication use in patients with obsessive-compulsive disorder (OCD) in seven different countries on five continents and to compare these with international treatment guidelines. MethodsResearchers in the field of OCD were invited to contribute summary statistics on the characteristics of their patients with OCD and on their incidence of psychotropic use. Consistency of summary statistics across countries was evaluated. ResultsThe data came from Brazil (n=955), Italy (n=750), South Africa (n=555), Japan (n=382), Australia (n=213), India (n=202) and Spain (n=82). The majority (77.9%; n=2445) of the total sample of 3139 participants received a psychotropic medication. Consistent with international guidelines, selective serotonin reuptake inhibitors (SSRIs) were most commonly used (73.5%, n=1796), but their use ranged from 59% in Australia to 96% in Japan. Clomipramine use varied from 5% in Japan and South Africa to 26% in India and Italy. Atypical antipsychotic use ranged from 12% in South Africa to 50% in Japan. ConclusionsPharmacotherapy for OCD varied significantly across sites. Prospective studies are required to determine the cultural, pharmacoeconomic and pharmacogenomic factors that may play a role in the variation in prescribing practices internationally and whether these variations influence treatment outcomes.
Palavras-chave
cross-cultural study, obsessive-compulsive disorder, pharmacotherapy, medication, selective serotonin re-uptake inhibitors, antipsychotics, benzodiazepines
URI
https://observatorio.fm.usp.br/handle/OPI/16310
Referências
  1. A. P. A, 2007, TREATM PAT OBS COMP
  2. Baldwin DS, 2014, J PSYCHOPHARMACOL, V28, P403, DOI 10.1177/0269881114525674
  3. Bandelow B, 2008, WORLD J BIOL PSYCHIA, V9, P248, DOI 10.1080/15622970802465807
  4. Bandelow B, 2012, INT J PSYCHIAT CLIN, V16, P77, DOI 10.3109/13651501.2012.667114
  5. Brakoulias V, 2013, AUSTRALAS PSYCHIATRY, V21, P117, DOI 10.1177/1039856212470502
  6. Brown T. A., 1994, ANXIETY DISORDERS IN
  7. Burroughs VJ, 2002, J NATL MED ASSOC, V94, P1
  8. Catapano F, 2010, PROG NEURO-PSYCHOPH, V34, P323, DOI 10.1016/j.pnpbp.2009.12.007
  9. Chakraborty A, 1975, INDIAN J PSYCHIAT, V17, P211
  10. COX BJ, 1993, J BEHAV THER EXP PSY, V24, P149, DOI 10.1016/0005-7916(93)90043-V
  11. Diniz JB, 2004, J CLIN PSYCHIAT, V65, P22
  12. do Rosario-Campos MC, 2001, AM J PSYCHIAT, V158, P1899, DOI 10.1176/appi.ajp.158.11.1899
  13. Eisen JL, 2013, J CLIN PSYCHIAT, V74, P233, DOI [10.4088/JCP.12m07657, 10.4088/ICP.12m07657]
  14. First MB, 2007, SCID I P
  15. GOODMAN WK, 1989, ARCH GEN PSYCHIAT, V46, P1006
  16. Kapczinski F, 2001, SUBST USE MISUSE, V36, P1053, DOI 10.1081/JA-100104489
  17. Dunker CIL, 2008, THEOR PSYCHOL, V18, P223, DOI 10.1177/0959354307087883
  18. Marazziti D, 2005, J PSYCHOPHARMACOL, V19, P392, DOI 10.1177/0269881105053299
  19. Marazziti D, 2010, EXPERT OPIN PHARMACO, V11, P331, DOI 10.1517/14656560903446948
  20. Matsunaga H, 2008, AM J PSYCHIAT, V165, P251, DOI 10.1176/appi.ajp.2007.07020340
  21. Mayerovitch JI, 2003, COMPR PSYCHIAT, V44, P162, DOI 10.1053/comp.2003.50005
  22. NICE, 2005, OBS COMP DIS COR INT
  23. Perugi G, 2002, J CLIN PSYCHIAT, V63, P1129
  24. Richards DA, 2009, BRIT J CLIN PSYCHOL, V48, P377, DOI 10.1348/014466509X405178
  25. Rosenberg S, 2010, AUSTRALAS PSYCHIATRY, V18, P496, DOI 10.3109/10398562.2010.525642
  26. Ruscio AM, 2010, MOL PSYCHIATR, V15, P53, DOI 10.1038/mp.2008.94
  27. Schruers K, 2005, ACTA PSYCHIAT SCAND, V111, P261, DOI 10.1111/j.1600-0447.2004.00502.x
  28. Sheehan D, 2010, MINI INT NEUROPSYCHI
  29. Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi
  30. Skoog G, 1999, ARCH GEN PSYCHIAT, V56, P121, DOI 10.1001/archpsyc.56.2.121
  31. Sorsdahl K, 2013, REV BRAS PSIQUIATR, V35, P136, DOI 10.1590/1516-4446-2012-0978
  32. Starcevic V, 2016, INT CLIN PSYCHOPHARM, V31, P27, DOI 10.1097/YIC.0000000000000100
  33. Stein DJ, 1996, CNS SPECTRUMS, V1, P42
  34. Van Ameringen M, 2014, J PSYCHOPHARMACOL

Coleções
Artigos e Materiais de Revistas Científicas - FM/MPS
Artigos e Materiais de Revistas Científicas - HC/IPq
Artigos e Materiais de Revistas Científicas - LIM/21